ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2% vs 2.0, odds ratio 0.608; p=0.024).
Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
The purpose of this bill is to incorporate the Universal Declaration on Bioethics and Human Rights into Australian law, to hold those that violate and abuse human rights to account, and to bring them to justice. I commend this bill to the House, and I call on the government to urgently bring it up for debate and for a vote and let history record where every member of this parliament sits on this issue.
Altogether, this study brings the proof of concept that an IVM-based immunomodulatory therapy improves the clinical condition of SARS-CoV-2-infected hamsters, and in clinical trials, it alleviates symptoms of COVID-19 in humans and possibly limits post-COVID-19 syndrome (also known as long COVID) via an anti-inflammatory action.
The results not only provide a structural basis for the anti-SARS-CoV-2 activity of HCQ, but also renders HCQ to be the first known drug capable of targeting LLPS.
Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.
Major benefits of ivermectin (IVM) treatment for COVID-19 have been known since the results of 20 such randomized controlled trials (RCTs) were reported
Significant QT prolongation was not observed during the follow‐up period compared with the baseline values in the present study. No ventricular arrhythmias, second and third‐degree heart blocks, or severe pauses were recorded during the treatment period.
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.
Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.
Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.
The purpose of this study was to assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 for being health personnel from
Ivermectin had a significant effect (p=0.003) in achieving medical release. The treatment with ivermectin could significantly prevent the evolution to serious stages since the experimental group did not present any patient with referral to critical hospitalization.
Reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally.
In this study, by use of DIC microscopy and NMR spectroscopy, for the first time we have decoded that HCQ specifically binds to both N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their interactions with nucleic acids (NAs), as well as to disrupt its NA-induced liquid-liquid phase separation (LLPS) essential for the viral life cycle including the package of gRNA and N protein into new virions.
Ivermectin is an effective treatment for COVID-19. The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (p = 0.00000000000023).
We conclude that two-dose ivermectin prophylaxis at a dose of 300 μg/kg body weight with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among HCWs in the following one month. Chemoprophylaxis has relevance in the containment of pandemic. This is an intervention worth replicating at other centers until a vaccine is widely available.
•TNR4 is a multidrug therapy (Ivermectin, Azithromycin, Montelukast and ASA) for COVID-19 cases.
•TNR4 increased the likelihood of recovery 3.4 times in ambulatory COVID-19 cases.
•The multidrug therapy TNR4 reduced the risk of hospitalization by 75%.
•The multidrug therapy TNR4 reduced the risk of death by 81%.
The dose used in the RECOVERY trial, arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.
We tested the hypothesis that aerosolized HCQ sulfate (aHCQ) tolerably, safely, and rapidly achieves high respiratory tissue concentrations, while minimizing systemic toxicity.
American Journal of Medicine announces peer-reviewed early outpatient treatment protocol for Covid19 including hydroxychloroquine. Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal. In the absence of clinical trials and guidelines, with hospitalizations and mortality mounting, it is prudent to deploy treatment for COVID-19 based on pathophysiological principles.
Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew
Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison, these are the total dose in the first two days
Source: Research Gate SHOUMAN WM1, HEGAZY AA2, NAFAE RM3, RAGAB ME4, SAMRA SR5, ANAS D6, AL-MAHROUKY TH7, SILEEM AE8DO – 10.7860/JCDR/2020/46795.0000 INTRODUCTION An outbreak of
In this study of COVID-19, for infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization
Maintaining an average hydroxychloroquine whole blood level above 1,068 ng/mL significantly reduced the risk of thrombosis in adults with systemic lupus.
HCQ is effective for COVID-19. The chance that an ineffective treatment generated results as positive as the 187 studies to date is 1 in 5 quadrillion (p = 0.00000000000000019).
Source: PubMed Petri M, Konig MF, Li J, Goldman DW. Higher Hydroxychloroquine Blood Levels Are Associated with Reduced Thrombosis Risk in Systemic Lupus Erythematosus. Arthritis
Hydroxychloroquine is an effective molecule against COVID-19 infection, many RCTs and observational studies, affirmed the benefits on virological clearance.
No cases of sudden death were observed. From publication, we have treated 3,119 patients with HCQ-AZ for at least three days.
Early SMDT (sequenced multidrug therapy) should be a standard practice in high risk & severely symptomatic acute COVID-19 patients at the onset of illness.
Bengal has released this document to state their COVID-19 policies, which include the use of HCQ. Well done Bengal.
The early use of
hydroxychloroquine decreased the improvement time
and the duration of COVID-19 detection in throat and
stool swabs.
Adjunct Prof John SkerrittDeputy SecretaryHealth Products Regulation GroupJohn.Skerritt@health.gov.auGPO Box 9848, Canberra, ACT Dear Professor Skerritt,We are writing to express our concerns regarding the role of
Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version 28, December 4, 2020) • HCQ is effective for COVID-19.
Source: Research Square. Augusto Di Castelnuovo, Mediterranea Cardiocentro, NapoliSimona Costanzo, Department of Epidemiology and Prevention, IRCCS Neuromed, PozzilliAntonio Cassone, Polo della genomica, genetica e biologia,
Source: swprs.org On the Treatment of Covid-19 Updated: November 16, 2020; Published: July 2, 2020 Immunological and serological studies show that most people develop only mild
Results obtained in the prophylaxis of Q fever indicate that chloroquine/hydroxychloroquine can be successfully used in the clinical management of infections other than malaria.
Source: Science Direct Tran Duc Anh Ly, Didier Zanini, Vincent Laforge, Sylvie Arlotto, Stephanie Gentile, Helene Mendizabal, Michael Finaud, David Morel, Olivier Quenette, Priscilla Malfuson-Clot-Faybesse,
Source: Science Direct Eman Sheshah, Shaun Sabico, Rashed M. Albakr, Anmar A. Sultan, Khalaf S. Alghamdi, Khaled Al Madani, Hadil A. Alotair, Nasser M. Al-Daghri,Prevalence
Source: Science Direct Simova I, Vekov T, Krasnaliev J, Kornovski V, Bozhinov P,Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health care workers, New Microbesand
